Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Wu M, Pedroza M, Lafyatis R, George AT, Mayes MD, Assassi S, Tan FK, Brenner MB, Agarwal SK.

Arthritis Rheumatol. 2014 Apr;66(4):1010-21. doi: 10.1002/art.38275.

2.

The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.

Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheumatol. 2014 Nov;66(11):3140-50. doi: 10.1002/art.38819.

3.

Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2).

Kanno Y, Kawashita E, Kokado A, Okada K, Ueshima S, Matsuo O, Matsuno H.

Arthritis Rheum. 2013 Feb;65(2):492-502. doi: 10.1002/art.37767. Erratum in: Arthritis Rheum. 2014 Jun;66(6):1671.

4.

Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.

Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N.

Arthritis Rheum. 2004 Jan;50(1):216-26.

5.

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, Palumbo K, Zwerina J, Nevskaya T, Gay S, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2010 Jan;62(1):280-90. doi: 10.1002/art.25056.

6.

Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.

Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, Jiménez SA.

Arthritis Rheum. 2008 Sep;58(9):2854-65. doi: 10.1002/art.23791.

7.

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH.

Arthritis Rheum. 2012 May;64(5):1642-52. doi: 10.1002/art.33501.

8.

An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.

Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, Goulet L, Lafyatis R, Tager AM.

Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. doi: 10.1002/art.39797.

PMID:
27390295
9.

Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.

Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, De Paulis A, Ibba-Manneschi L, Matucci-Cerinic M.

Ann Rheum Dis. 2017 May;76(5):924-934. doi: 10.1136/annrheumdis-2016-210229. Epub 2017 Jan 6.

PMID:
28062404
10.

CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.

Vorstenbosch J, Al-Ajmi H, Winocour S, Trzeciak A, Lessard L, Philip A.

Arthritis Rheum. 2013 May;65(5):1378-83. doi: 10.1002/art.37907.

11.

Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S.

Arthritis Rheumatol. 2015 Feb;67(2):517-26. doi: 10.1002/art.38948.

12.

Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.

Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, Wang XJ, DiPietro LA, Varga J.

Am J Pathol. 2004 Jul;165(1):203-17.

13.

Osteopontin in systemic sclerosis and its role in dermal fibrosis.

Wu M, Schneider DJ, Mayes MD, Assassi S, Arnett FC, Tan FK, Blackburn MR, Agarwal SK.

J Invest Dermatol. 2012 Jun;132(6):1605-14. doi: 10.1038/jid.2012.32. Epub 2012 Mar 8.

14.

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O.

Arthritis Rheum. 2010 Jun;62(6):1733-43. doi: 10.1002/art.27443.

15.

Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.

Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, Trojanowska M, Gilliam AC, Varga J.

Arthritis Rheum. 2005 Apr;52(4):1248-58.

16.

Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis.

Tomcik M, Palumbo-Zerr K, Zerr P, Sumova B, Avouac J, Dees C, Distler A, Becvar R, Distler O, Schett G, Senolt L, Distler JH.

Ann Rheum Dis. 2016 Mar;75(3):609-16. doi: 10.1136/annrheumdis-2014-206234. Epub 2015 Jan 20.

PMID:
25603829
17.

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.

Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, Horn A, Zerr P, Zwerina J, Gelse K, Distler O, Schett G, Distler JH.

Arthritis Rheum. 2012 Sep;64(9):3006-15. doi: 10.1002/art.34500.

18.

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sato S.

Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

19.

Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.

Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B.

Arthritis Rheum. 2007 Jan;56(1):334-44.

20.

A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.

Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S.

Exp Dermatol. 2016 Apr;25(4):287-92. doi: 10.1111/exd.12920. Epub 2016 Feb 11.

PMID:
26661692

Supplemental Content

Support Center